期刊文献+
任意字段
题名或关键词
题名
关键词
文摘
作者
第一作者
机构
刊名
分类号
参考文献
作者简介
基金资助
栏目信息

1例Tarceva与Avastin联合用药致皮肤黏膜改变的观察及护理

下载PDF
导出
作者 闫有梅 王海燕 赵诣
机构地区 中国医学科学院中国协和医科大学北京协和医院特需医疗部一段七病房
出处 《现代护理》 2006年第27期2624-2624,共1页 Modern Nursing
关键词 抗肿瘤药物 酷氨酸激酶抑制剂 血管内皮生长因子 不良反应 护理
分类号 R472 [医药卫生—护理学]
  • 相关文献

参考文献7

  • 1李龙芸,穆新林.肺癌化疗进展[J].中国肺癌杂志,2003,6(6):450-455. 被引量：11
  • 2Hurwitz.Bevacizumab Prolongs Survival in first-line Colorectal cancer(CRC):results of a phase Ⅲ trial of bevacizumab in combination with bolus IFL as first-line therapy in subjects with metastatic CRC[M].Proc:ASCOM,2003:3 646.
  • 3Hurwitz.Phase Ⅱrandomized trial comparing bevacizumab plus fluorouracil(FU)/Ieucovorin(LV) with FU/LV alone in patients with metastatic colorectal cancer[M].Proc:ASCOM,2003:3 646.
  • 4王鹏,陈震,黄雯霞.抗VEGF单抗Avastin(bevacizumab)在肿瘤治疗中的应用研究进展[J].国际肿瘤学杂志,2004,31(S1):1-4. 被引量：5
  • 5Hidalgo M.TarcevaTM:a potent HERI/EGFR-tyrosine kinase inhibitor[J].Lung Cancer,2003,41(3):115.
  • 6Perez Soler R.TarcevaTM-associated rash to maximize treatment outcome?[J].Lung Cancer,2003,41(3):117.
  • 7Iqbal S,Lens HJ.Angiogenesis inhibitors in the treatment of colorectal cancer[J].Sein Oncol,2004,31 (17):6-10.

二级参考文献33

  • 1[1]Schiller JH. Influential papers since the last IASLC conference: cytotoxic therapy. Lung Cancer,2003,41(Suppl 3)∶S86.
  • 2[2]Socinski MA. Optimal number of cytotoxic agents and chemotherapy cycles for advanced NSCLC. Lung Cancer,2003, 41(Suppl 3)∶S93.
  • 3[3]Smith IE, O'Brien ME, Talbot DC, et al. Duration of chemotherapy in advanced non-small-cell lung cancer: a randomized trial of three versus six courses of mitomycin, vinblastine, and cisplatin. J Clin Oncol,2001,19(5)∶1336-1343.
  • 4[4]Socinski MA, Schell MJ, Peterman A, et al. Phase Ⅲ trial comparing a defined duration of therapy versus continuous therapy followed by second-line therapy in advanced-stage ⅢB/Ⅳ non-small-cell lung cancer. J Clin Oncol,2002,20(5)∶1335-1343.
  • 5[5]Depierre A, Quoix E, Mercier M, et al. Maintenance chemotherapy in advanced non-small cell lung cancer (NSCLC): A randomized study of vinorelbine (v) versus observation (ob) in patients (pts) responding to induction therapy (French Cooperative Oncology Group). Proc Am Soc Clin Onc,2001,20p∶309a.
  • 6[6]Fukuoka M. Epidermal growth factor receptor tyrosine kinase inhibitors: single agent therapy. Lung Cancer,2003,41(Suppl 3)∶S38.
  • 7[7]Goss G. Gefitinib ("Iressa"): The patients' experience. Lung Cancer,2003,41(Suppl 3)∶112.
  • 8[8]Herbst RS. Targeting the EGFR: prognostic and clinical implications. Lung Cancer,2003,41(Suppl 3)∶S114.
  • 9[9]Lynch T. Clinical benefit in NSCLC: The evidence for gefitinib ("Iressa"). Lung Cancer,2003,41(Suppl 3)∶S116.
  • 10[10]Hidalgo M. TarcevaTM: a potent HER1/EGFR-tyrosine kinase inhibitor. Lung Cancer,2003,41(Suppl 3)∶S115.

共引文献14

现代护理
2006年 第27期

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部